Tools   Select Another Resource Report Type

http://clinicaltrials.gov/show/NCT01211678

A consortium evaluating a new biomarker screening test that might help identify patients with rheumatoid arthritis (RA) who are unlikely to benefit from anti-tumor necrosis factor-alpha (TNFalpha) medications. BATTER-UP will enroll around 1,000 patients being treated by one of several marketed anti-TNF RA drugs: Enbrel, Remicade, Humira, Simponi, or Cimzia. Through data analyses and predictive response modeling, the consortium aims to better understand which patients with RA will derive the greatest benefit from TNF inhibitors. The investigators in this observational study will attempt to validate an 8-gene biomarker set based on work by Biogen Idec researchers as likely to predict anti-TNF responsiveness in patients with RA. In preliminary results, the 8-gene biomarker set predicted with 89% accuracy individuals who did not reach European League Against Rheumatism (EULAR) Disease Activity Score (DAS)-28 good response after 14 weeks of treatment. The 8 genes included in the screen are CLTB, MXRA7, CXorf52, COL4A3BP, YIPF6, FAM44A, SFRS2, and PGK1. Biological samples and clinical outcome information will be used to confirm and extend the utility of previously published biomarkers that can predict response to anti-TNF agents. These data may also generate new hypotheses for further testing. The BATTER-UP samples and data will be established as a reference set for investigation of personalized medicine in RA. The study will be a resource of DNA and other biological materials that can be investigated for biomarkers in the future as new technologies arise.

Proper citation: Biomarkers of Anti-TNF Treatment Efficacy in Rheumatoid Arthritis - Unresponsive Populations (RRID:SCR_004019) Copy   

•   Source: SciCrunch Registry

http://sourceforge.net/projects/seqexpress/

A cross-platform software that estimates gene/isoform expression level via mRNA-Seq data. SeqExpress exams the Sequencing bias in mRNA-Seq and correct it to get more accurate estimation.

Proper citation: SeqExpress (RRID:SCR_004013) Copy   

•   Source: SciCrunch Registry

http://datacatalog.med.nyu.edu/

A searchable data catalog that facilitates researchers'' access to large datasets available either publicly or through institutional or individual licensing. Dataset records include information about the content of the dataset, how to access the dataset, and local experts within NYULMC and NYU to assist in the use of these datasets. The data catalog will expand to include internally generated datasets from NYULMC and NYU in the near future. Use the contact form if you are interested in submitting a dataset to the data catalog.

Proper citation: NYU Data Catalog (RRID:SCR_004012) Copy   

•   Source: SciCrunch Registry

http://www.westonfoundation.org/

Foundation that gives grants in Canada for the benefit of Canadians and directs its resources to specific organizations in Education, Land Conservation and Science in Canada''s North. In addition, it provides funds to further Canada''s research in neuroscience. These programs are director-initiated and the Foundation therefore does not accept applications for funding. By law, the Foundation is only able to support Canadian charities that are registered with the Canadian Revenue Agency. These charities must have a CRA charitable number and offer programs benefiting Canadians in Canada.

Proper citation: W. Garfield Weston Foundation (RRID:SCR_004017) Copy   

•   Source: SciCrunch Registry

http://www.cxrbiosciences.com/

Commercial organization that provides preclinical services and expertise, specializing in investigative toxicology, exploratory and discovery toxicology, metabolism and pharmacokinetics. CXR Biosciences is now Concept Life Sciences.

Proper citation: CXR Biosciences (RRID:SCR_003961) Copy   

•   Source: SciCrunch Registry

http://www.alz.org/research/alzheimers_grants/biomarkers-across.asp

Consortium that launched a Request for Applications (RFA) to stimulate analyses across the Alzheimer's disease (AD) and Parkinson's disease (PD) research enterprises to engage in further data analysis of existing cohorts, including, but not limited to, biomarker discovery, standardization of assays, genetic profiles, and imaging modalities. The RFA aims to build on existing momentum to leverage similar activities and increase impact across the neurodegenerative disease spectrum. It also builds on recent evidence suggesting substantial overlap between AD, PD, and other neurodegenerative diseases pathologically, but also potentially biologically. The RFA is designed to enable preliminary pilot research or proof-of-principle studies utilizing data and/or samples from two large biomarker studies, the Alzheimer's Disease Neuroimaging Initiative (ADNI) and the Parkinson's Progression Markers Initiative (PPMI), in order to garner further research support from other funding agencies. Application Deadline: March 19, 2014. Efforts under BAND include studies that: * analyze datasets to test hypotheses related to aging and neurodegenerative disorders; * seek to identify panels or pathways that may play a role in disease mechanisms, such as around inflammation; * pursue shared or disparate biochemical markers of disease risk, onset or progression; * assess potential commonalities across the disease spectrum, including around other neurological disorders such as Lewy body dementia. Recent data reported at the 2013 Alzheimer's Association's International Conference stimulated discussion in the research community about the possible cross talk between AD and PD. For example, underlying pathologies / biomarkers, such as cerebrospinal fluid (CSF) alpha-synuclein, have been measured in the sample sets collected for both diseases to help understand similarities and differences in these diseases. Furthermore, similar imaging modalities, such as MRI and PET, are being employed to interrogate changes that occur with disease progression. As therapeutic approaches are developed that may be disease-modifying for several neurodegenerative diseases, stratification of clinical trial populations based on biomarker profiles may increase the probability of success in demonstrating a beneficial effect.

Proper citation: Biomarkers Across Neurodegenerative Diseases (RRID:SCR_004015) Copy   

•   Source: SciCrunch Registry

http://www.gabo-mi.com/

THIS RESOURCE IS OUT OF SERVICE, documented on July 23, 2021. Small and medium-sized enterprise (SME) that is expert in management of research projects. Initially, they provide support with help and advice when applying for European research grants - free of charge. From project start, they take over contract negotiations, financial management, reporting to the EC, meeting organization, public relations and much more. ARTTIC Innovation GmbH took over GAVBO:mi.

Proper citation: GABO:mi (RRID:SCR_003956) Copy   

•   Source: SciCrunch Registry

http://www.interfaceurope.eu/

THIS RESOURCE IS OUT OF SERVICE, documented on July 23, 2021.Commercial organization with expertise in European research and innovation that provide both science providers (researchers) and technology users (Industry including SMEs, public authorities, Universities, clusters, etc.) tailor-made services to give the highest possible European added value to their project.

Proper citation: Interface Europe (RRID:SCR_003955) Copy   

•   Source: SciCrunch Registry

http://www.epo-berlin.com/

A small and medium-sized enterprise (SME) that has expertise in preclinical pharmacology, pharmacokinetics, and toxicology for the characterization of novel anticancer therapeutics and predictive biomarkers like: cytostatics, biologicals (peptides, antibodies), (anti)-hormones, immunomodulators (cytokines), and gene therapeutics. EPO has modern laboratories licensed for animal experiments and gene technology (S2) and a broad panel of murine and human tumor models growing in immunocompetent (SPF-quality, syngeneic strains) or immunodeficient mice (nude, SCID, NOD/SCID). EPO has established imaging technologies to monitor in vivo tumor growth.

Proper citation: Experimental Pharmacology and Oncology Berlin-Buch (RRID:SCR_003954) Copy   

•   Source: SciCrunch Registry

http://www.alacris.de/

Commercial organization that uses next generation sequencing technologies coupled with computational modeling of tumor and somatic tissues in order to identify individualized therapies for cancer patients. The company also uses these technologies to help pharmaceutical partners stratify patients for their clinical trials. Alacris has an exclusive worldwide commercial license for the computational modeling of tumors and somatic tissues using proprietary computational systems modeling technologies ModCell developed at the Max Planck Institute for Molecular Genetics (MPI-MG) in Berlin coupled with next generation sequencing and genotyping technology developed at Harvard Medical School in Boston. The company also is building up the first next generation sequencing center in Europe for clinical operations.

Proper citation: Alacris Theranostics (RRID:SCR_003953) Copy   

•   Source: SciCrunch Registry

http://psynova.com/

Commercial organization focused on the development and exploitation of novel biomarkers for psychiatric illnesses. They provide industrial and academic partners with comprehensive biomarker discovery services in commercial and collaborative projects. They operate in the field of psychiatric disorders and their products and services are designed to excel biomarker research. In 2010, Psynova Neurotech and its partner company Rules-Based-Medicine Inc (now MyriadRBM) conducted a beta launch of a blood test aiding in the diagnosis of schizophrenia (http://www.veripsych.com/). They are now refining the test and have shifted their focus to the development of new blood-based biomarker tests that aid in the diagnosis, prognosis and differential diagnosis of schizophrenia, bipolar disorder and major depression. They offer not only their pre-selceted Multiple Reaction Monitoring (MRM) and Multiplex Immunoassay products, but also custom build panels. If they are provided with a list of analyses to evaluate, they can produce an analytical panel according to individual needs utilizing either MRM or Multiplex Immunoassay technologies., THIS RESOURCE IS NO LONGER IN SERVICE. Documented on September 16,2025.

Proper citation: Psynova Neurotech (RRID:SCR_003959) Copy   

•   Source: SciCrunch Registry

http://www.thecommunityguide.org/uses/funding.html

http://www.thecommunityguide.org/uses/funding.html

Proper citation: Coordinating center for infectious diseases (RRID:SCR_003958) Copy   

•   Source: SciCrunch Registry

http://biodbcore.org

A community-defined, uniform, generic description of the core attributes of biological databases. The BioDBCore checklist is overseen by the International Society for Biocuration (ISB), in collaboration with the BioSharing forum. A catalogue of databases, described according to the BioDBcore guidelines, along with the standards used within them have been partly compiled with the support of Oxford University Press and Re3Data.org. Database providers are encouraged to either create or claim their BioDBCore entry and update it as appropriate., THIS RESOURCE IS NO LONGER IN SERVICE. Documented on January 15,2026.

Proper citation: bioDBcore (RRID:SCR_002781) Copy   

•   Source: SciCrunch Registry

https://www.drugabuse.gov/publications/drugfacts/genetics-epigenetics-addiction

THIS RESOURCE IS NO LONGER IN SERVICE, documented on July 17, 2013. An archived video on the web providing comprehensive and hands-on training in genetics and epigenetic methodology. The purpose of the course is to provide an introduction to approaches and tools for identifying genes that confer vulnerability to addiction and individual differences in responses to treatments. The course is targeted to those who are new to the field of addiction genetics. The course was held over 5 days with lectures and hands-on demonstrations given each day. Viewers of the course will gain familiarity with conceptual and practical approaches to complex disorders using relevant genetic and epigenetic databases, and appropriate statistical and empirical approaches. Topics covered Behavioral genetics, genetic epidemiology, twin and adoption studies, statistical genetic concepts and approaches for mapping complex traits, haplotype based approaches for association mapping, genome-wide scans for addictive disorders, application of linkage for mapping genes and genetic loci for addictive disorders, pharmacogenomics of treatment of addictive disorders, Baysian Methods for identifying gene-gene interactions, analysis of copy number variation, practical use of genetic databases, mapping of complex traits in mice, methods for analyzing gene expression, and methods for doing epigenetic analysis are covered. The course was held April 4, 2008, at the Bethesda North Marriott Hotel and Conference Center, 5701 Marinelli Road, Bethesda, MD 20852.

Proper citation: Short Course on the Genetics and Epigenetics of Addiction National Institute on Drug Abuse: Archived Video (RRID:SCR_002783) Copy   

•   Source: SciCrunch Registry

http://genespeed.ccf.org/home/

THIS RESOURCE IS NO LONGER IN SERVICE, documented on July 16, 2013. Database and customized tools to study the PFAM protein domain content of the transcriptome for all expressed genes of Homo sapiens, Mus musculus, Drosophila melanogaster, and Caenorhabditis elegans tethered to both a genomics array repository database and a range of external information resources. GeneSpeed has merged information from several existing data sets including the Gene Ontology Consortium, InterPro, Pfam, Unigene, as well as micro-array datasets. GeneSpeed is a database of PFAM domain homology contained within Unigene. Because Unigene is a non-redundant dbEST database, this provides a wide encompassing overview of the domain content of the expressed transcriptome. We have structured the GeneSpeed Database to include a rich toolset allowing the investigator to study all domain homology, no matter how remote. As a result, homology cutoff score decisions are determined by the scientist, not by a computer algorithm. This quality is one of the novel defining features of the GeneSpeed database giving the user complete control of database content. In addition to a domain content toolset, GeneSpeed provides an assortment of links to external databases, a unique and manually curated Transcription Factor Classification list, as well as links to our newly evolving GeneSpeed BetaCell Database. GeneSpeed BetaCell is a micro-array depository combined with custom array analysis tools created with an emphasis around the meta analysis of developmental time series micro-array datasets and their significance in pancreatic beta cells.

Proper citation: GeneSpeed- A Database of Unigene Domain Organization (RRID:SCR_002779) Copy   

•   Source: SciCrunch Registry

http://liulab.dfci.harvard.edu/BINOCh/

Software that infers the identity of transcription factors used to regulate cell response to stimulus or determine a program of differentiation. It uses genome wide information on enhancer proximal nucleosome occupancy, acquired using ChIP-seq targeting enhancer related histone modifications., THIS RESOURCE IS NO LONGER IN SERVICE. Documented on January 15,2026.

Proper citation: BINOCh (RRID:SCR_002778) Copy   

•   Source: SciCrunch Registry

http://www.nikoninstruments.com/Products/Software/NIS-Elements-Basic-Research

Software tool for acquisition and device control for standard research applications, requiring four dimensional imaging. Provides access to advanced image capture, archiving, and analysis solutions that are easy-to-use and provide maximum workflow. Handles multi dimensional imaging with support for capture, display, data management, analysis and additional options for peripheral device control, and multi-dimensional acquisition. Provides advanced image processing options such as database capabilities and report generation, intensity over time measurement, and Extended Depth of Focus functionality.

Proper citation: NIS-Elements Basic Research (RRID:SCR_002776) Copy   

•   Source: SciCrunch Registry

http://www.cbil.upenn.edu/RAD

THIS RESOURCE IS NO LONGER IN SERVICE, Documented on March 24, 2014. A resource for gene expression studies, storing highly curated MIAME-compliant studies (i.e. experiments) employing a variety of technologies such as filter arrays, 2-channel microarrays, Affymetrix chips, SAGE, MPSS and RT-PCR. Data were available for querying and downloading based on the MGED ontology, publications or genes. Both public and private studies (the latter viewable only by users having appropriate logins and permissions) were available from this website. Specific details on protocols, biomaterials, study designs, etc., are collected through a user-friendly suite of web annotation forms. Software has been developed to generate MAGE-ML documents to enable easy export of studies stored in RAD to any other database accepting data in this format. RAD is part of a more general Genomics Unified Schema (http://gusdb.org), which includes a richly annotated gene index (http://allgenes.org), thus providing a platform that integrates genomic and transcriptomic data from multiple organisms. NOTE: Due to changes in technology and funding, the RAD website is no longer available. RAD as a schema is still very much active and incorporated in the GUS (Genomics Unified Schema) database system used by CBIL (EuPathDB, Beta Cell Genomics) and others. The schema for RAD can be viewed along with the other GUS namespaces through our Schema Browser.

Proper citation: RNA Abundance Database (RRID:SCR_002771) Copy   

•   Source: SciCrunch Registry

http://learn.genetics.utah.edu/content/addiction/

A physiologic and molecular look at drug addiction involving many factors including: basic neurobiology, a scientific examination of drug action in the brain, the role of genetics in addiction, and ethical considerations. Designed to be used by students, teachers and members of the public, the materials meet selected US education standards for science and health. Drug addiction is a chronic disease characterized by changes in the brain which result in a compulsive desire to use a drug. A combination of many factors including genetics, environment and behavior influence a person's addiction risk, making it an incredibly complicated disease. The new science of addiction considers all of these factors - from biology to family - to unravel the complexities of the addicted brain. * Natural Reward Pathways Exist in the Brain: The reward pathway is responsible for driving our feelings of motivation, reward and behavior. * Drugs Alter the Brain's Reward Pathway: Drugs work over time to change the reward pathway and affect the entire brain, resulting in addiction. * Genetics Is An Important Factor In Addiction: Genetic susceptibility to addiction is the result of the interaction of many genes. * Timing and Circumstances Influence Addiction: If you use drugs when you are an adolescent, you are more likely to develop lifetime addiction. An individual's social environment also influences addiction risk. * Challenges and Issues in Addiction: Addiction impacts society with many ethical, legal and social issues.

Proper citation: New Science of Addiction: Genetics and the Brain (RRID:SCR_002770) Copy   

•   Source: SciCrunch Registry

http://www.genedb.org/Homepage

Database of genomes at various stages of completion, from early access to partial genomes with automatic annotation through to complete genomes with extensive manual curation. Its primary goals are: 1) to provide reliable access to the latest sequence data and annotation/curation for the whole range of organisms sequenced by the Pathogen group, and 2) to develop the website and other tools to aid the community in accessing and obtaining the maximum value from these data.

Proper citation: GeneDB (RRID:SCR_002774) Copy   

•   Source: SciCrunch Registry